Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-06-13 11:38 am Purchase |
2025-06-09 | 13G | UroGen Pharma Ltd. URGN |
Cowen Financial Products LLC | 2,652,500 5.800% |
2,652,500 (New Position) |
Filing History |
| 2025-06-09 7:19 pm Sale |
2025-06-05 | 13D | UroGen Pharma Ltd. URGN |
Monograph Capital Holdings Advisors, LLC | 838,615 1.900% |
-823,712 (-49.55%) |
Filing History |
| 2025-05-15 4:53 pm Unchanged |
2025-03-31 | 13G | UroGen Pharma Ltd. URGN |
RA CAPITAL MANAGEMENT L.P. | 3,206,271 7.000% |
0 (Unchanged) |
Filing History |
| 2025-05-12 09:02 am Sale |
2025-03-31 | 13G | UroGen Pharma Ltd. URGN |
Adage Capital Management, L.P. | 1,277,000 2.770% |
-1,651,086 (-56.39%) |
Filing History |
| 2025-03-17 1:23 pm Unchanged |
2025-03-11 | 13G | UroGen Pharma Ltd. URGN |
MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 4.990% |
0 (Unchanged) |
Filing History |
| 2025-02-12 09:34 am Sale |
2024-12-31 | 13G | UroGen Pharma Ltd. URGN |
Adage Capital Management, L.P. | 2,928,086 6.940% |
-807,655 (-21.62%) |
Filing History |
| 2025-02-05 10:09 am Sale |
2024-12-31 | 13G | UroGen Pharma Ltd. URGN |
MORGAN STANLEY MS |
752,861 1.800% |
-1,419,466 (-65.34%) |
Filing History |
| 2024-11-18 06:16 am Purchase |
2024-03-14 | 13D | Eloxx Pharmaceuticals, Inc. ELOX |
Pontifax Management III G.P. (2011) Ltd. | 1,485,168 4.400% |
1,448,564 (+3957.37%) |
Filing History |
| 2024-11-14 7:46 pm Sale |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
Point72 Asset Management, L.P. | 1,520,007 3.600% |
-1,049,819 (-40.85%) |
Filing History |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
RA CAPITAL MANAGEMENT L.P. | 3,206,271 7.100% |
122,713 (+3.98%) |
Filing History |
| 2024-11-14 4:47 pm Sale |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
Great Point Partners, LLC | 758,786 1.800% |
-1,861,759 (-71.04%) |
Filing History |
| 2024-11-14 12:04 pm Unchanged |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 5.470% |
0 (Unchanged) |
Filing History |
| 2024-11-14 08:37 am Unchanged |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
COWEN AND COMPANY, LLC | 1,796,589 4.300% |
0 (Unchanged) |
Filing History |
| 2024-11-14 06:44 am Purchase |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
RTW Investments, LP | 4,930,204 9.990% |
3,203,396 (+185.51%) |
Filing History |
| 2024-11-12 09:30 am Purchase |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
Adage Capital Management, L.P. | 3,735,741 8.870% |
3,735,741 (New Position) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
BlackRock Inc. BLK |
2,497,943 5.900% |
0 (Unchanged) |
Filing |
| 2024-11-06 1:50 pm Purchase |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
MORGAN STANLEY MS |
2,172,327 5.200% |
2,172,327 (New Position) |
Filing History |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | UroGen Pharma Ltd. URGN |
BlackRock Inc. BLK |
2,497,943 5.900% |
828,400 (+49.62%) |
Filing |
| 2024-06-24 5:25 pm Purchase |
2024-06-19 | 13G | UroGen Pharma Ltd. URGN |
COWEN AND COMPANY, LLC | 1,796,589 4.360% |
1,796,589 (New Position) |
Filing History |
| 2024-06-24 4:51 pm Purchase |
2024-06-14 | 13G | UroGen Pharma Ltd. URGN |
Point72 Asset Management, L.P. | 2,569,826 6.200% |
2,569,826 (New Position) |
Filing History |